BRPI0411900B8 - compostos e composições farmacêuticas compreendendo os mesmos - Google Patents
compostos e composições farmacêuticas compreendendo os mesmosInfo
- Publication number
- BRPI0411900B8 BRPI0411900B8 BRPI0411900A BRPI0411900A BRPI0411900B8 BR PI0411900 B8 BRPI0411900 B8 BR PI0411900B8 BR PI0411900 A BRPI0411900 A BR PI0411900A BR PI0411900 A BRPI0411900 A BR PI0411900A BR PI0411900 B8 BRPI0411900 B8 BR PI0411900B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pharmaceutical compositions
- methods
- antiviral
- relates
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000840 anti-viral effect Effects 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
- C07D241/34—(Amino-pyrazine carbonamido) guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003903251A AU2003903251A0 (en) | 2003-06-26 | 2003-06-26 | Antiviral compounds and methods |
| AU2003903850A AU2003903850A0 (en) | 2003-07-25 | 2003-07-25 | Anti-coronavirus compounds and methods |
| AU2003904692A AU2003904692A0 (en) | 2003-08-29 | Anti-flavivirus compounds and methods | |
| AU2004902902A AU2004902902A0 (en) | 2004-05-31 | Anti-flavivirus compounds and methods | |
| PCT/AU2004/000866 WO2004112687A2 (en) | 2003-06-26 | 2004-06-26 | Antiviral acylguanidine compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0411900A BRPI0411900A (pt) | 2006-09-19 |
| BRPI0411900B1 BRPI0411900B1 (pt) | 2018-11-21 |
| BRPI0411900B8 true BRPI0411900B8 (pt) | 2021-05-25 |
Family
ID=33545379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0411900A BRPI0411900B8 (pt) | 2003-06-26 | 2004-06-26 | compostos e composições farmacêuticas compreendendo os mesmos |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20130035328A1 (https=) |
| EP (2) | EP2617709B8 (https=) |
| JP (1) | JP5030587B2 (https=) |
| KR (1) | KR101153254B1 (https=) |
| BR (1) | BRPI0411900B8 (https=) |
| CA (1) | CA2529949C (https=) |
| NZ (1) | NZ544671A (https=) |
| WO (1) | WO2004112687A2 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2617709B8 (en) | 2003-06-26 | 2022-12-21 | Biotron Limited | Guanidine derivatives as antiviral agents |
| US7745442B2 (en) * | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| AU2013205388B2 (en) * | 2005-06-24 | 2016-05-05 | Biotron Limited | Antiviral compounds and methods |
| NZ596107A (en) * | 2005-06-24 | 2013-09-27 | Biotron Ltd | Antiviral compounds and methods |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0526240D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| ES2563477T3 (es) * | 2007-08-03 | 2016-03-15 | Biotron Limited | Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina |
| AU2013219202B2 (en) * | 2007-08-03 | 2016-12-08 | Biotron Limited | Hepatitis C antiviral compositions and methods |
| WO2010039195A2 (en) * | 2008-09-23 | 2010-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Screening for inhibitors of hcv amphipathic helix (ah) function |
| BR122020020745B8 (pt) | 2010-07-22 | 2023-10-31 | Gilead Sciences Inc | Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| SI3349758T1 (sl) | 2015-09-16 | 2022-08-31 | Gilead Sciences, Inc. | Postopki za zdravljenje okužb z virusom arenaviridae |
| WO2018081863A1 (en) * | 2016-11-04 | 2018-05-11 | University Of Wollongong | 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF |
| US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| JP2021138619A (ja) * | 2020-03-02 | 2021-09-16 | フマキラー株式会社 | 抗コロナウイルス剤 |
| JP7554841B2 (ja) | 2020-03-12 | 2024-09-20 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシドを調製する方法 |
| WO2021202550A1 (en) * | 2020-03-30 | 2021-10-07 | Thomas Jefferson University | Compounds, compositions, and methods for treating, ameliorating, or preventing viral infections |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| US20220054575A1 (en) * | 2020-08-19 | 2022-02-24 | Natreon, Inc. | Protection against coronavirus infection by extracts and extract components |
| AU2021330835B2 (en) | 2020-08-24 | 2023-12-14 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
| EP3960165A1 (en) * | 2020-08-25 | 2022-03-02 | Fondation EspeRare | Nhe-1 inhibitors for the treatment of coronavirus infections |
| SI4204421T1 (sl) | 2020-08-27 | 2024-07-31 | Gilead Sciences, Inc., | Spojine in postopki za zdravljenje virusnih okužb |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| EP4346772B1 (en) | 2021-05-26 | 2026-04-01 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| WO2023012329A1 (en) | 2021-08-06 | 2023-02-09 | Intervet International B.V. | Method of treating veterinary viral diseases |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| KR20240154646A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| IL315102A (en) | 2022-03-02 | 2024-10-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| WO2023167055A1 (ja) * | 2022-03-03 | 2023-09-07 | 日本曹達株式会社 | 抗ウイルス剤 |
| PE20250419A1 (es) | 2022-03-03 | 2025-02-14 | Gilead Sciences Inc | Compuestos antivirales y metodos de elaboracion y uso de los mismos |
| JP2025508941A (ja) | 2022-03-03 | 2025-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス化合物並びにその作製及び使用方法 |
| JP2025519390A (ja) | 2022-06-06 | 2025-06-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２を含むウイルス感染の治療方法 |
| WO2024006376A1 (en) | 2022-06-29 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024112712A1 (en) * | 2022-11-21 | 2024-05-30 | Henderson Theodore | Treatment using an antiviral compound and spironolactone |
| WO2024173458A1 (en) | 2023-02-16 | 2024-08-22 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| IL326322A (en) | 2023-08-31 | 2026-04-01 | Gilead Sciences Inc | Antiviral compounds and methods for their production and use |
| US20250090537A1 (en) | 2023-08-31 | 2025-03-20 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250099476A1 (en) | 2023-09-06 | 2025-03-27 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20250109157A1 (en) | 2023-09-28 | 2025-04-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2734904A (en) * | 1956-02-14 | Xcxnhxc-nh | ||
| BE639386A (https=) | 1962-10-30 | |||
| FR1435379A (fr) * | 1964-07-30 | 1966-04-15 | American Cyanamid Co | Procédé pour stabiliser le chlorure de polyvinyle rigide contre les effets de la lumière |
| US3527758A (en) * | 1967-04-13 | 1970-09-08 | Merck & Co Inc | Process for the preparation of pyrazinoylguanidines from a pyrazinoic azide and a guanidine |
| DE2006186A1 (de) | 1970-02-11 | 1971-08-19 | Huebner Vamag | Verfahren zum Einsetzen eines Sitz ringes fur den Absperrkorper einer Armatur |
| DE2531343A1 (de) * | 1975-07-14 | 1977-02-10 | Henkel & Cie Gmbh | Antimikrobielle mittel |
| DD200618A1 (de) * | 1981-10-05 | 1983-05-25 | Manfred Augustin | Verfahren zur herstellung von neuen n-aroyl-und hetaroylimiden |
| US4496573A (en) * | 1982-08-24 | 1985-01-29 | William H. Rorer, Inc. | 1-Pyridylmethyl-3-acyl guanidines |
| US4894376A (en) * | 1988-02-26 | 1990-01-16 | Trustees Of The University Of Pennsylvania | Methods of treating diseases characterized by hyperexcitability of neurons |
| JPH0789859A (ja) * | 1990-04-05 | 1995-04-04 | Celtrix Pharmaceut Inc | ピラジン誘導体を含む薬剤学的組成物と眼の新血管新生を阻止する治療法 |
| IN177137B (https=) * | 1992-12-11 | 1996-11-16 | Hoechst India | |
| DE4301739A1 (de) * | 1993-01-22 | 1994-07-28 | Sauer Professor Dr Gerhard | Guanidin-Derivate zur Behandlung von Primär-Tumoren und viralen Erkrankungen |
| JPH0725768A (ja) * | 1993-07-09 | 1995-01-27 | Mitsubishi Chem Corp | 血管内膜肥厚抑制剤 |
| DE4325822A1 (de) * | 1993-07-31 | 1995-02-02 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| TW415937B (en) * | 1994-01-25 | 2000-12-21 | Hoechst Ag | Phenyl-substituted alkylcarboxylic acid guanidides bearing perfluoroalkyl groups, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| DE4415873A1 (de) * | 1994-05-05 | 1995-11-09 | Hoechst Ag | Substituierte bizyklische Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4421536A1 (de) * | 1994-06-20 | 1995-12-21 | Hoechst Ag | Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| JPH08225513A (ja) * | 1994-12-21 | 1996-09-03 | Kanebo Ltd | ナフトイルグアニジン誘導体 |
| AT408330B (de) | 1995-01-27 | 2001-10-25 | Colop Stempelerzeugung Skopek | Selbstfärbestempel |
| DK0738712T3 (da) * | 1995-04-18 | 2000-03-06 | Hoechst Ag | Substituerede indenoylguanidiner med antiarytmetisk kardioprotektiv virkning |
| DE19518796A1 (de) * | 1995-05-22 | 1996-11-28 | Hoechst Ag | Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19527305A1 (de) * | 1995-07-26 | 1997-01-30 | Hoechst Ag | Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| JPH0967332A (ja) * | 1995-08-29 | 1997-03-11 | Yamanouchi Pharmaceut Co Ltd | Ｎ−（２−プロペノイル）グアニジン誘導体 |
| DE19621482A1 (de) * | 1996-05-29 | 1997-12-04 | Hoechst Ag | Substituierte 1-Naphthoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19622222A1 (de) * | 1996-06-03 | 1997-12-04 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide |
| AUPO545297A0 (en) * | 1997-03-04 | 1997-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
| IL126276A0 (en) * | 1997-09-24 | 1999-05-09 | Hoechst Marion Roussel De Gmbh | The use of an inhibitor of the na+/H+ exchanger for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system |
| EP1032556B1 (en) * | 1997-10-21 | 2007-12-19 | Wyeth a Corporation of the State of Delaware | Pharmaceutically active compounds and methods of use |
| US7041702B1 (en) * | 1997-10-21 | 2006-05-09 | Scion Pharmaceuticals, Inc. | Pharmaceutically active compounds and methods of use |
| JP2002508507A (ja) * | 1997-12-18 | 2002-03-19 | セプラコア インコーポレーテッド | 新規な生物学的標的および創薬リード構造体の同時同定方法 |
| US6011059A (en) * | 1997-12-24 | 2000-01-04 | Bristol-Myers Squibb Company | Acyl guanidine sodium/proton exchange inhibitors and method |
| AUPP646498A0 (en) | 1998-10-12 | 1998-11-05 | Australian National University, The | A method of modulating ion channel functional activity |
| DE19849722A1 (de) * | 1998-10-28 | 2000-05-04 | Aventis Pharma Gmbh | Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19859727A1 (de) * | 1998-12-23 | 2000-06-29 | Aventis Pharma Gmbh | Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung |
| AUPQ223999A0 (en) * | 1999-08-16 | 1999-09-09 | University Of Sydney, The | Intracellular feedback controls in the diagnosis and treatment of human disease |
| AUPS022802A0 (en) * | 2002-01-31 | 2002-02-21 | Macfarlane Burnet Institute For Medical Research And Public Health Limited, The | Anti-viral compounds |
| EP2617709B8 (en) | 2003-06-26 | 2022-12-21 | Biotron Limited | Guanidine derivatives as antiviral agents |
| NZ596107A (en) * | 2005-06-24 | 2013-09-27 | Biotron Ltd | Antiviral compounds and methods |
-
2004
- 2004-06-26 EP EP13164504.6A patent/EP2617709B8/en not_active Expired - Lifetime
- 2004-06-26 KR KR1020057024860A patent/KR101153254B1/ko not_active Expired - Fee Related
- 2004-06-26 BR BRPI0411900A patent/BRPI0411900B8/pt not_active IP Right Cessation
- 2004-06-26 WO PCT/AU2004/000866 patent/WO2004112687A2/en not_active Ceased
- 2004-06-26 JP JP2006515560A patent/JP5030587B2/ja not_active Expired - Lifetime
- 2004-06-26 EP EP04737487A patent/EP1646371A4/en not_active Withdrawn
- 2004-06-26 CA CA2529949A patent/CA2529949C/en not_active Expired - Lifetime
- 2004-06-26 NZ NZ544671A patent/NZ544671A/en not_active IP Right Cessation
-
2012
- 2012-07-19 US US13/553,239 patent/US20130035328A1/en not_active Abandoned
-
2015
- 2015-02-06 US US14/615,616 patent/US20150313909A1/en not_active Abandoned
-
2017
- 2017-05-23 US US15/602,526 patent/US10472332B2/en not_active Expired - Lifetime
-
2019
- 2019-08-29 US US16/554,990 patent/US11192863B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20170260147A1 (en) | 2017-09-14 |
| BRPI0411900A (pt) | 2006-09-19 |
| EP1646371A4 (en) | 2010-09-22 |
| EP2617709B1 (en) | 2022-11-16 |
| JP2007508234A (ja) | 2007-04-05 |
| US20190389816A1 (en) | 2019-12-26 |
| US20130035328A1 (en) | 2013-02-07 |
| US11192863B2 (en) | 2021-12-07 |
| WO2004112687A2 (en) | 2004-12-29 |
| EP2617709A1 (en) | 2013-07-24 |
| CA2529949C (en) | 2013-08-06 |
| CA2529949A1 (en) | 2004-12-29 |
| US20150313909A1 (en) | 2015-11-05 |
| EP1646371A2 (en) | 2006-04-19 |
| KR20060103086A (ko) | 2006-09-28 |
| BRPI0411900B1 (pt) | 2018-11-21 |
| JP5030587B2 (ja) | 2012-09-19 |
| US10472332B2 (en) | 2019-11-12 |
| NZ544671A (en) | 2009-02-28 |
| EP2617709B8 (en) | 2022-12-21 |
| WO2004112687A3 (en) | 2007-07-12 |
| KR101153254B1 (ko) | 2012-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0411900B8 (pt) | compostos e composições farmacêuticas compreendendo os mesmos | |
| BR122020006906B8 (pt) | compostos e composições farmacêuticas antivirais | |
| CR8273A (es) | Administracion de ligandos de tlr7 y profarmacos de los mismos para el tratamiento de la infeccion por el virus de hepetitis c | |
| BRPI0418251C1 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| BR0316680A (pt) | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos | |
| UY27714A1 (es) | 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos. | |
| EA200601007A1 (ru) | 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы | |
| BRPI0416936A (pt) | sistemas de anel de imidazo substituìdos e métodos | |
| EA200700363A1 (ru) | Фосфонатные аналоги соединений ингибиторов вич | |
| BR0208636A (pt) | Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com infncia | |
| BRPI0417571A (pt) | 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-ciclohexil-alquila substituìda como inibidores da poli(adp-ribose) polimerase | |
| DK1556021T3 (da) | Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger | |
| BRPI0410029B8 (pt) | composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto | |
| ATE418554T1 (de) | 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen | |
| BRPI0312649A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| UA95103C2 (ru) | Замещенные арилсульфонамиды в качестве противовирусных средств | |
| HN2003000038A (es) | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico | |
| NO20052310L (no) | Posisjonsisomerer av PEG IFN alfa 2A. | |
| BR0314195A (pt) | Derivados de piridina substituìda como agentes antitumorais | |
| BRPI0515518A (pt) | análogos de loxapina e métodos de usos dos mesmos | |
| CL2004000710A1 (es) | Composicion antimicrobiana y antiparasitaria formada por un antibiotico derivado del cloranfenicol o tianfenicol, un endectocida y por lo menos un vehiculo aceptable, y su uso para tratar enfermedades respiratorias y parasitarias de los bovinos. | |
| PT1299395E (pt) | Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus | |
| BRPI0507626A (pt) | compostos e composiçoes como moduladores de lxr | |
| CL2004002030A1 (es) | Uso de interferon y ribavirina porque sirve para preparar un medicamento para tratar infecciones virales; composicion farmaceutica que comprende interferon, ribavirina y opcionalmente antioxidante; kit y su uso para preparar un medicamento para trata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: "PARA: INT. CL. A61K 31/00 Ipc: A61K 31/00 (2011.01), A61P 31/00 (2011.01), A61P 3 Free format text: PARA: INT. CL. A61K 31/00; A61P 31/00, 31/12 Ipc: A61K 31/00 (2011.01), A61P 31/00 (2011.01), A61P 3 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |